AR015759A1 - HYDEROCICLIC DERIVATIVE COMPOUND OF GLICIL D-ALANINE, PHARMACEUTICAL COMPOSITION CONTAINING IT AND METHOD TO TREAT AFFECTIONS - Google Patents
HYDEROCICLIC DERIVATIVE COMPOUND OF GLICIL D-ALANINE, PHARMACEUTICAL COMPOSITION CONTAINING IT AND METHOD TO TREAT AFFECTIONSInfo
- Publication number
- AR015759A1 AR015759A1 ARP990101636A ARP990101636A AR015759A1 AR 015759 A1 AR015759 A1 AR 015759A1 AR P990101636 A ARP990101636 A AR P990101636A AR P990101636 A ARP990101636 A AR P990101636A AR 015759 A1 AR015759 A1 AR 015759A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- alkoxy
- amino
- group
- carboxyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente se relaciona con una clase de compuestos representados por la formula (I) donde el grupo (II) es un anillo heterocíclico monocíclico de 5-8miembros, insaturado optativamente que contiene de 1 a 4 heteroátomos, seleccionados del grupo formado por O, N o S, donde X1 se selecciona del grupo formadopor CH, CH2, N, NH, O y S; A es la formula (III) donde Y1 se selecciona del grupo formado por N-R2, O, y S; R2 se selecciona del grupo formado por H, alquilo,arilo, hidroxi, alcoxi, ciano, nitro, amino, alquenilo, alquinilo, amida, alquilcarbonilo, arilcarbonilo, alcoxicarbonilo, ariloxicarbonilo,haloalquilcarbonilo, haloalcoxicarbonilo, alquiltiocarbonilo, ariltiocarbonilo, aciloximetoxicarbonilo, alquilo sustituido optativamente con unoo mássustituyentes seleccionados entre alquilo inferior, halogeno, hidroxilo, haloalquilo, ciano, nitro, carboxilo, amino, alcoxi, arilo o arilo sustituidooptativamente con uno o más grupos halogeno, haloalquilo, alquilo inferior, alcoxi, ciano, alquilsulfonilo, alquiltio, nitro, carboxilo, amino, hidroxilo,ácido sulfonico, sulfonamida, arilo, arilo fusionado, heterociclos monocíclicos o heterociclos monocíclicos fusionados, arilo sustituido optativamente con unoo más sustituyentes seleccionados entre grupos halogeno, haloalquilo, hidroxi, alquilo inferior, alcoxi, metilendioxi, etilendioxi, ciano, nitro, alquiltio,alquilsulfonilo, ácido sulfonico, sulfonamida, derivados de carboxilo, amino, arilo, arilo fusionado, heterociclos monocíclicos y heterociclos monocíclicosfusionados, heterociclos monocíclicos y heterociclos monocíclicos sustituidos optativamente con uno o más sustituyentes seleccionados entre grupos halogeno,haloalquilo, alquilo inferior, alcoxi, amino, nitro, hidroxi, derivados de carboxilo, ciano, alquiltio, alquilsulfonilo, ácido sulfonico, sulfonamida, arilo oarilo fusionado; o R2 tomado junto con R7, forma un dinitrogeno de 4-12 miembros que contiene heterociclo sustituido optativamente con uno o más sustituyentesseleccionados del grupo formado por alquilo inferior, tioalquilo, alquilamino, hidroxi, ceto, alcoxi, halo, fenilo, amino, carboxilo o carboxiléster y feniloThis is related to a class of compounds represented by formula (I) where group (II) is a 5-8-member monocyclic heterocyclic ring, optionally unsaturated containing 1 to 4 heteroatoms, selected from the group consisting of O, N or S, where X1 is selected from the group consisting of CH, CH2, N, NH, O and S; A is the formula (III) where Y1 is selected from the group consisting of N-R2, O, and S; R2 is selected from the group consisting of H, alkyl, aryl, hydroxy, alkoxy, cyano, nitro, amino, alkenyl, alkynyl, amide, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylthiocarbonyl, acyloxytoxycarbonyl, acyloxytoxycarbonyl, acyloxymethyl with one or more substituents selected from lower alkyl, halogen, hydroxyl, haloalkyl, cyano, nitro, carboxyl, amino, alkoxy, aryl or aryl optionally substituted with one or more halogen, haloalkyl, lower alkyl, alkoxy, cyano, alkylsulfonyl, alkylthio, nitro groups, carboxyl, amino, hydroxyl, sulfonic acid, sulfonamide, aryl, fused aryl, monocyclic heterocycles or fused monocyclic heterocycles, aryl optionally substituted with one or more substituents selected from halogen, haloalkyl, hydroxy, lower alkyl, alkoxy, methylenedioxy, ethylenedioxy, cyano groups nitro, alkylthio, alkylsulfonyl, sulfonic acid, su lfonamide, carboxyl, amino, aryl, fused aryl, monocyclic and fused monocyclic heterocycles, monocyclic heterocycles and monocyclic heterocycles optionally substituted with one or more substituents selected from halogen, haloalkyl, lower alkyl, alkoxy, amino, nitro, hydroxy groups of carboxyl, cyano, alkylthio, alkylsulfonyl, sulfonic acid, sulfonamide, fused aryl oaryl; or R2 taken together with R7, forms a 4-12 membered dinitrogen containing heterocycle optionally substituted with one or more substituents selected from the group consisting of lower alkyl, thioalkyl, alkylamino, hydroxy, keto, alkoxy, halo, phenyl, amino, carboxyl or carboxylester and phenyl
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8139498P | 1998-04-10 | 1998-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR015759A1 true AR015759A1 (en) | 2001-05-16 |
Family
ID=22163868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990101636A AR015759A1 (en) | 1998-04-10 | 1999-04-09 | HYDEROCICLIC DERIVATIVE COMPOUND OF GLICIL D-ALANINE, PHARMACEUTICAL COMPOSITION CONTAINING IT AND METHOD TO TREAT AFFECTIONS |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1070060A1 (en) |
JP (1) | JP2002511462A (en) |
KR (1) | KR20010042614A (en) |
CN (1) | CN1304406A (en) |
AR (1) | AR015759A1 (en) |
AU (1) | AU765294B2 (en) |
BR (1) | BR9910119A (en) |
CA (1) | CA2326665A1 (en) |
CZ (1) | CZ20003672A3 (en) |
IL (1) | IL138677A0 (en) |
MY (1) | MY133473A (en) |
NO (1) | NO20005084L (en) |
NZ (1) | NZ507292A (en) |
PL (1) | PL343406A1 (en) |
RU (1) | RU2215746C2 (en) |
TW (1) | TWI247008B (en) |
WO (1) | WO1999052896A1 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6172256B1 (en) * | 1998-03-04 | 2001-01-09 | G.D. Searle & Co. | Chiral-β-amino acid compounds and derivatives thereof |
GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
KR20010110310A (en) * | 1998-12-23 | 2001-12-12 | 로저 에이. 윌리암스 | Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
EP1156803A4 (en) | 1999-02-09 | 2004-03-17 | Bristol Myers Squibb Co | LACTAM INHIBITORS OF FXa AND METHOD |
AU769554B2 (en) | 1999-04-12 | 2004-01-29 | Aventis Pharma Limited | Substituted bicyclic heteroaryl compounds as integrin antagonists |
GB9908355D0 (en) * | 1999-04-12 | 1999-06-09 | Rhone Poulenc Rorer Ltd | Chemical compounds |
RU2001132141A (en) * | 1999-04-28 | 2004-03-20 | БАСФ Акциенгезельшафт (DE) | INTEGRIN RECEPTOR ANTAGONISTS |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
EP1332132B1 (en) | 2000-04-17 | 2007-10-10 | UCB Pharma, S.A. | Enamine derivatives as cell adhesion molecules |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
WO2001096310A1 (en) * | 2000-06-15 | 2001-12-20 | Pharmacia Corporation | Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists |
US6511973B2 (en) | 2000-08-02 | 2003-01-28 | Bristol-Myers Squibb Co. | Lactam inhibitors of FXa and method |
AU2001275724A1 (en) | 2000-08-02 | 2002-02-13 | Celltech R&D Limited | 3-substituted isoquinolin-1-yl derivatives |
DE10204789A1 (en) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Inhibitors of the integrin alpha¶v¶beta6 |
TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
AU2003299600A1 (en) * | 2002-12-20 | 2004-07-29 | Pharmacia Corpration | The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
JP5366960B2 (en) | 2007-10-18 | 2013-12-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | CGRP antagonist |
EP2065381A1 (en) | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP antagonists |
EP2225237A2 (en) * | 2007-11-22 | 2010-09-08 | Boehringer Ingelheim International GmbH | Organic compounds |
WO2009065919A2 (en) | 2007-11-22 | 2009-05-28 | Boehringer Ingelheim International Gmbh | Novel compounds |
US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
EP2875021B1 (en) | 2012-07-18 | 2017-08-23 | Saint Louis University | Beta amino acid derivatives as integrin antagonists |
CA2950390C (en) | 2014-05-30 | 2020-09-22 | Pfizer Inc. | Carbonitrile derivatives as selective androgen receptor modulators |
EP3294716B1 (en) | 2015-12-30 | 2020-04-15 | Saint Louis University | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists |
KR102515507B1 (en) * | 2016-11-08 | 2023-03-28 | 브리스톨-마이어스 스큅 컴퍼니 | Pyrrolamide as an alpha V integrin inhibitor |
JPWO2021230325A1 (en) * | 2020-05-14 | 2021-11-18 | ||
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
WO2023085396A1 (en) * | 2021-11-12 | 2023-05-19 | Ube株式会社 | Pharmaceutical composition for providing treatment for or preventing alport syndrome |
CN115626912B (en) * | 2022-09-27 | 2024-03-26 | 中山大学 | Thiourea compound and preparation method and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5120859A (en) * | 1989-09-22 | 1992-06-09 | Genentech, Inc. | Chimeric amino acid analogues |
DK0850221T3 (en) * | 1995-08-30 | 2001-09-24 | Searle & Co | Meta-guanidine, urea, thiourea or azacyclic aminobenzoic acid derivatives as intergrin antagonists |
DE19629816A1 (en) * | 1996-07-24 | 1998-01-29 | Hoechst Ag | New cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists |
EP0934305A4 (en) * | 1996-08-29 | 2001-04-11 | Merck & Co Inc | Integrin antagonists |
-
1999
- 1999-04-09 AR ARP990101636A patent/AR015759A1/en unknown
- 1999-04-09 NZ NZ507292A patent/NZ507292A/en unknown
- 1999-04-09 EP EP99916119A patent/EP1070060A1/en not_active Withdrawn
- 1999-04-09 IL IL13867799A patent/IL138677A0/en unknown
- 1999-04-09 CA CA002326665A patent/CA2326665A1/en not_active Abandoned
- 1999-04-09 PL PL99343406A patent/PL343406A1/en unknown
- 1999-04-09 KR KR1020007011291A patent/KR20010042614A/en not_active Application Discontinuation
- 1999-04-09 RU RU2000128033/04A patent/RU2215746C2/en not_active IP Right Cessation
- 1999-04-09 CZ CZ20003672A patent/CZ20003672A3/en unknown
- 1999-04-09 WO PCT/US1999/004297 patent/WO1999052896A1/en not_active Application Discontinuation
- 1999-04-09 AU AU34499/99A patent/AU765294B2/en not_active Ceased
- 1999-04-09 JP JP2000543454A patent/JP2002511462A/en active Pending
- 1999-04-09 CN CN99807091A patent/CN1304406A/en active Pending
- 1999-04-09 BR BR9910119-0A patent/BR9910119A/en not_active IP Right Cessation
- 1999-04-09 TW TW088105718A patent/TWI247008B/en active
- 1999-04-10 MY MYPI99001398A patent/MY133473A/en unknown
-
2000
- 2000-10-09 NO NO20005084A patent/NO20005084L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU765294B2 (en) | 2003-09-11 |
EP1070060A1 (en) | 2001-01-24 |
KR20010042614A (en) | 2001-05-25 |
CN1304406A (en) | 2001-07-18 |
JP2002511462A (en) | 2002-04-16 |
MY133473A (en) | 2007-11-30 |
AU3449999A (en) | 1999-11-01 |
CA2326665A1 (en) | 1999-10-21 |
NO20005084L (en) | 2000-11-27 |
RU2215746C2 (en) | 2003-11-10 |
CZ20003672A3 (en) | 2001-08-15 |
BR9910119A (en) | 2001-10-09 |
NO20005084D0 (en) | 2000-10-09 |
TWI247008B (en) | 2006-01-11 |
NZ507292A (en) | 2003-12-19 |
WO1999052896A1 (en) | 1999-10-21 |
PL343406A1 (en) | 2001-08-13 |
IL138677A0 (en) | 2001-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR015759A1 (en) | HYDEROCICLIC DERIVATIVE COMPOUND OF GLICIL D-ALANINE, PHARMACEUTICAL COMPOSITION CONTAINING IT AND METHOD TO TREAT AFFECTIONS | |
ECSP941085A (en) | DERIVATIVES OF AMIDA, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM | |
AR016429A1 (en) | COMPOUND DERIVED FROM HYDROXAMIC ACID AS MATRIX METALOPROTEASE (MMP) INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND VETERINARY FORMULATIONS, USOPARES THE PREPARATION OF COMPOSITIONS AND FORMULATIONS, INTERMEDIARY COMPOUND, PROCEDURE FOR PREPARATION OF COMPOSITION. | |
ES2182535T3 (en) | BENZO DERIVATIVES (B) TIEPINA-1, -DIOXIDE, PROCEDURE FOR PREPARATION, MEDICATIONS CONTAINING THESE COMPOUNDS AND THEIR USE. | |
EA200600257A1 (en) | DERIVATIVES OF TRIAZOLOPYRIMIDINE AS KINASE GLYCOGENSINTAZY-3 KINASE INHIBITORS | |
BRPI0810929B8 (en) | use of a compound of formula 1 | |
AR038863A1 (en) | USE OF A GARFT AND / OR AICARFT INHIBITOR AND AN ANTITOXIC AGENT TO PREPARE A DRUG TO SELECTLY DESTROY MTAP-DEFICIENT CELLS FROM A MAMMER | |
AR055360A1 (en) | MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS | |
RU2000128033A (en) | Heterocyclic derivatives of glycyl-beta-alanine as vitronectin antagonists | |
PE20021005A1 (en) | QUINAZOLINES AS INHIBITORS OF MMP-13 | |
EA200601852A1 (en) | TETRAHYDROCHINOLINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION | |
WO2007149448A3 (en) | Pyrazinones as cellular proliferation inhibitors | |
ATE491704T1 (en) | 4-Ä2-(CYCLOALKYLAMINO)PYRIMIDINE-4-YLÜ-(PHENYL)IMIDAZOLINE-2-ONE DERIVATIVES AS INHIBITORS OF P38 MAP KINASE FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
HU0102723D0 (en) | New diphenylurea derivatives, process for their preparation and pharmaceutical compositions containing them | |
AR068376A1 (en) | USEFUL HETEROCICLIC AMIDAS TO INHIBIT THE VIA HEDGEHOG. | |
PE20050160A1 (en) | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | |
DK435583D0 (en) | PROCEDURE FOR THE PREPARATION OF HETEROCYCLIC DERIVATIVES OF CYCLOBUTAN | |
AR038842A1 (en) | ANTIPARASITARIAN ARTEMISININE DERIVATIVES (ENDOPEROXIDS) | |
AR026222A1 (en) | COMPOUNDS DERIVED FROM ANTRANILIC ACID | |
AR017097A1 (en) | COMPOUNDS OF 2- (3H) -OXAZOLONA, USEFUL AS SELECTIVE COX-2 INHIBITORS; PROCEDURE TO PREPARE SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FORMED WITH SUCH COMPOUNDS | |
EA201070197A1 (en) | DERIVATIVES 1-OXO-IZOINDOLIN-4-CARBOXAMIDES AND 1-OXO-1,2,3,4-TETRAHYDRO-ISOHINOLIN-5-CARBOXAMIDES, METHOD FOR THEIR RECEPTION AND APPLICATION IN THERAPY | |
EA199900608A1 (en) | NEW PHARNESILTRANSFERASE INHIBITORS, METHODS FOR THEIR PRODUCTION, CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION FOR THE PRODUCTION OF MEDICUMENTS | |
TR200103286T2 (en) | Cyclocarbamate derivatives as progesterone receptor modulators | |
SE8306764L (en) | NEW ETHENDIAMIN AND GUANIDINE DERIVATIVES | |
PT90097A (en) | PROCESS FOR THE PREPARATION OF NEW 5,7-DIHYDRO-PYRROLE (3,2-F) BENZOXAZOL-6-ONES SUBSTITUTED BY HETEROCYCLIC SUBSTITUTS, AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |